Andrew L. Phillips
A5072352114- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- Respiratory viral infections research
- SARS-CoV-2 detection and testing
- Influenza Virus Research Studies
- COVID-19 epidemiological studies
- Musculoskeletal pain and rehabilitation
- Pain Management and Opioid Use
- Opioid Use Disorder Treatment
- Infection Control and Ventilation
- Retinal and Optic Conditions
- Animal Virus Infections Studies
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 and healthcare impacts
- Ethics and Legal Issues in Pediatric Healthcare
- Kawasaki Disease and Coronary Complications
- Viral Infections and Outbreaks Research
- Biosensors and Analytical Detection
- Bone and Joint Diseases
- Management of metastatic bone disease
- Medical Imaging and Pathology Studies
- Mobile Crowdsensing and Crowdsourcing
- Hepatitis C virus research
University of Utah
2019-2025
Rocky Mountain University of Health Professions
2019-2025
University of Arizona
2022-2023
University of Miami
2022
University of Utah Health Care
2021
National Institute for Occupational Safety and Health
2020
University of Southern California
2011
Children's Hospital of Los Angeles
2011
Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic randomized placebo-controlled Phase III trials (1,2); however, the benefits of these for asymptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered real-world conditions, is less well understood. Using prospective cohorts health care personnel, first responders, other essential frontline workers* eight U.S....
Information is limited regarding the effectiveness of two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attenuating disease 2019 (Covid-19) when administered real-world conditions.
The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for persons aged 12-15 years (referred to as adolescents in this report) May 12, 2021, and children 5-11 November 2, 2021 (1-4). Real-world data effectiveness (VE) these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant United States December early investigations of VE demonstrated a decline protection against symptomatic...
Importance Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, 5 to 11 October 12, 2022; however, data demonstrating effectiveness of bivalent are limited. Objective To assess against SARS-CoV-2 infection symptomatic among adolescents. Design, Setting, Participants Data period 4, January 31, 2023, combined from 3 prospective cohort studies (6 sites total) used estimate vaccine 17 years. A total 2959 participants...
In a cohort of essential workers in the United States previously infected with SARS-CoV-2, risk factors for reinfection included being unvaccinated, infrequent mask use, time since first infection, and non-Hispanic Black. Protecting from requires multipronged approach including up-to-date vaccination, use as recommended, reduction underlying health disparities.
Importance An estimated 1% to 3% of children with SARS-CoV-2 infection will develop post–COVID-19 condition (PCC). Objective To evaluate the odds PCC among COVID-19 vaccination prior compared unvaccinated children. Design, Setting, and Participants In this case-control study, were enrolled in a multisite longitudinal pediatric cohort from July 27, 2021, September 1, 2022, followed up through May 2023. Analysis used case (PCC reported)–control (no reported) design included aged 5 17 years...
Workers critical to emergency response and continuity of essential services during the COVID-19 pandemic are at a disproportionally high risk SARS-CoV-2 infection. Prospective cohort studies needed for enhancing understanding incidence symptomatic asymptomatic infections, identifying factors, assessing clinical outcomes, determining effectiveness vaccination.The Research on Epidemiology in Essential Response Personnel (RECOVER) prospective study was designed estimate examine factors...
American College of Occupational and Environmental Medicine's (ACOEM's) evidence-based guidelines for acute low back pain (LBP) were used to assess relationships between guideline adherence worker's compensation costs.Treatments at first appointments abstracted. Two scoring tools utilized each patient's treatment plan. One score assessed ACOEM Guideline compliance while the second mean expert scores perceived value treatment. Claim costs log-transformed compared with scores.There is a...
ABSTRACT BACKGROUND Information is limited on messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection or attenuating disease when administered real-world conditions. METHODS Prospective cohorts of 3,975 healthcare personnel, first responders, other essential frontline workers completed weekly testing during December 14 2020—April 10 2021. Self-collected mid-turbinate nasal swabs were tested by qualitative...
Abstract Background We sought to evaluate the impact of changes in estimates COVID‐19 vaccine effectiveness on incidence laboratory‐confirmed infection among frontline workers at high risk for SARS‐CoV‐2. Methods analyzed data from a prospective worker cohort estimate by month as well association vaccination, occupation, demographics, physical distancing, and mask use with risk. Participants completed baseline quarterly surveys, each week self‐collected mid‐turbinate nasal swabs reported...
Approximately 12 million children and adolescents aged ≤18 years in the United States have been infected with SARS-CoV-2, virus that causes COVID-19, since December 2019,* COVID-19-associated hospitalization rates increased among <5 during B.1.617.2 (Delta) B.1.1.529(Omicron) variant peaks (1).In June 2022, Food Drug Administration amended Emergency Use Authorization for BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine to include use of 6 months-4 mRNA-1273 (Moderna) months-5 years, which CDC...
Abstract Background Immunogenicity studies suggest that recombinant influenza vaccine (RIV) may provide better protection against than standard-dose inactivated vaccines (SD IIV). This randomized trial evaluated the relative effectiveness (VE) and immunogenicity of RIV versus SD IIV in frontline workers students aged 18–64 years. Methods Participants were to receive or followed for reverse-transcription polymerase chain reaction (RT-PCR)–confirmed during 2022–2023 season. Sera collected from...
Abstract Background Previous estimates of vaccine effectiveness (VE) against asymptomatic influenza virus infection based on seroconversion have varied widely and may be biased. We estimated 2022–2023 VE illness in a prospective cohort. Methods In the HEROES-RECOVER cohort, adults at increased occupational risk exposure across 7 US sites provided weekly symptom reports nasal swabs for reverse transcription–polymerase chain reaction (RT-PCR) testing. Laboratory-confirmed infections were...
Assessing the real-world effectiveness of COVID-19 vaccines and understanding incidence severity SARS-CoV-2 illness in children are essential to inform policy guide health care professionals advising parents caregivers who test positive for SARS-CoV-2.This report describes objectives methods conducting Pediatric Research Observing Trends Exposures Timelines (PROTECT) study. PROTECT is a longitudinal prospective pediatric cohort study designed estimate vaccine (VE) against infection among...
Abstract Background Data on antibody kinetics are limited among individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From a cohort of healthcare personnel and other frontline workers in 6 US states, we assessed waning after messenger RNA (mRNA) dose response to 3 according SARS-CoV-2 infection history. Methods Participants submitted sera every months, infection, each mRNA vaccine dose. Sera were tested for antibodies reported as area under the...
Objective: The aim of this study was to determine the efficacy an evidence-based opioid guidelines-based program implemented at largest worker's compensation insurer in Utah. Methods: All new claims, including surgeries, were included. Pre- and post-intervention comparisons included percentage claims treated with opioid, provision a second prescription, use above 50 mg morphine equivalent dose (MED), more than 90 MED, over days. Results: There significant (P < 0.001) reductions all primary...
Pediatric COVID-19 vaccine hesitancy and uptake is not well understood. Among parents of a prospective cohort children aged 6 months-17 years, we assessed knowledge, attitudes, practices (KAP), over 15 months.
Abstract Background There are limited data on whether hybrid immunity differs by count and order of immunity-conferring events (infection with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] or vaccination against disease 2019 [COVID-19]). From a multi-site cohort frontline workers, we examined the heterogeneity effect SARS-CoV-2 antibody levels. Methods Exposures included event order, categorized into 7 permutations. Outcome was level serum antibodies receptor-binding domain...
Hybrid immunity, as a result of infection and vaccination to SARS-CoV-2, has been well studied in adults but limited evidence is available children. We evaluated the antibody responses primary SARS-CoV-2 among vaccinated unvaccinated children aged ≥ 5 years. Methods: A longitudinal cohort study was conducted during August 2021–August 2022, at sites Arizona, Texas, Utah, Florida. Children submitted weekly nasal swabs for PCR testing provided sera 14–59 days after PCR-confirmed infection....
While there is evidence that COVID-19 vaccination protects against development of post-COVID conditions (PCC) after severe infection data are limited on whether reduces the risk cases less-severe non-hospitalized disease with more recent SARS-CoV-2 variant viruses. This study assessed was protective subsequent PCC in persons predominantly mild initial infections during both Delta and Omicron predominance.
Abstract To understand how COVID-19 vaccines impact infection risk in children &lt;5 years, we assessed of SARS-CoV-2 from Sept 2022–April 2023 three cohort studies. There was no difference by vaccination status. While reduce severe disease, they may not infections young children.
Objective: To assess the effect of morphine equivalent dose-days (MED-D) on total cost for acute low back pain (LBP) workers’ compensation claims. Methods: Simple random samples 123 opioid and 141 nonopioid LBP claims were obtained. Opioid divided into low, medium, high subgroups MED-D, MED, prescription duration. Subgroup mean costs compared to group using multivariate regression analyses. Results: MED-D duration each, respectively, associated with significantly increased at both medium...
Respiratory specimen collection materials shortages hampers severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We compared alternatives and evaluated SARS-CoV-2 RNA stability under simulated shipping conditions. concordance of RT-PCR detection from flocked midturbinate swabs (MTS) in viral transport media (VTM), foam MTS without VTM, saliva. Specimens were collected between August 2020 April 2021 three prospective cohorts. cycle quantification (
Background. We sought to evaluate the impact of changes in estimates COVID-19 vaccine effectiveness on incidence laboratory-confirmed infection among frontline workers at high risk for SARS-CoV-2. Methods. analyzed data from a prospective worker cohort estimate by month as well association vaccination, occupation, demographics, physical distancing and mask use with risk. Participants completed baseline quarterly surveys, each week self-collected mid-turbinate nasal swabs reported symptoms....
Currently, radiation therapy is widely used for the treatment and palliation of metastatic bone disease in both adults children. Recent advances therapy, such as intensity-modulated have led to more focused treatments fewer adverse effects. Although has been associated with several musculoskeletal effects growing child, hip dislocation during a course not reported. We report case 12-year-old girl who presented disease, developed therapy. Possible causes are discussed detail thorough...